IL324041A - Methods of treating hepatic-only metastatic uveal melanoma - Google Patents

Methods of treating hepatic-only metastatic uveal melanoma

Info

Publication number
IL324041A
IL324041A IL324041A IL32404125A IL324041A IL 324041 A IL324041 A IL 324041A IL 324041 A IL324041 A IL 324041A IL 32404125 A IL32404125 A IL 32404125A IL 324041 A IL324041 A IL 324041A
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Application number
IL324041A
Other languages
English (en)
Hebrew (he)
Inventor
Matthew Anthony Maurer
Yujiro Hata
Michael Gabriel O'quigley
Original Assignee
Ideaya Biosciences Inc
Pfizer
Matthew Anthony Maurer
Yujiro Hata
Oquigley Michael Gabriel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc, Pfizer, Matthew Anthony Maurer, Yujiro Hata, Oquigley Michael Gabriel filed Critical Ideaya Biosciences Inc
Publication of IL324041A publication Critical patent/IL324041A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL324041A 2023-04-21 2025-10-19 Methods of treating hepatic-only metastatic uveal melanoma IL324041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363497590P 2023-04-21 2023-04-21
PCT/US2024/025461 WO2024220839A1 (en) 2023-04-21 2024-04-19 Methods of treating hepatic-only metastatic uveal melanoma

Publications (1)

Publication Number Publication Date
IL324041A true IL324041A (en) 2025-12-01

Family

ID=93153246

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324041A IL324041A (en) 2023-04-21 2025-10-19 Methods of treating hepatic-only metastatic uveal melanoma

Country Status (6)

Country Link
EP (1) EP4698282A1 (de)
KR (1) KR20260005936A (de)
AU (1) AU2024259627A1 (de)
IL (1) IL324041A (de)
MX (1) MX2025012553A (de)
WO (1) WO2024220839A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200282015A1 (en) * 2017-09-22 2020-09-10 Washington University Targeted pharmacological therapeutics in uveal melanoma
US11679113B2 (en) * 2019-04-11 2023-06-20 The Regents Of The University Of California Anticancer treatment for uveal melanoma
WO2021155235A1 (en) * 2020-01-31 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating uveal melanoma
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療

Also Published As

Publication number Publication date
EP4698282A1 (de) 2026-02-25
WO2024220839A1 (en) 2024-10-24
MX2025012553A (es) 2026-01-07
KR20260005936A (ko) 2026-01-12
AU2024259627A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
IL295459A (en) Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL274386A (en) Androgen receptor modulator and uses thereof
IL255148B (en) 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
IL290727B1 (en) A formulation for inhibiting the formation of 5-ht 2b agonists and methods of using the same
IL257276A (en) Methods for treating Knox-Gestaut syndrome using penforamine
IL253048B2 (en) A pharmaceutical preparation for the treatment of cancer containing a lactate metal salt
IL256662A (en) Focusidase inhibitors
IL296990A (en) Methods for the treatment of multiple sclerosis relapse using an inhibitor of proton tyrosine kinase
IL278978B1 (en) Preparations and methods for treating psoriasis
IL292378A (en) Preparations that include a dhodh inhibitor for the treatment of acute myeloid leukemia
IL298071A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
IL298538A (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
IL296093A (en) Use of compounds in the treatment of fungal infections
IL324041A (en) Methods of treating hepatic-only metastatic uveal melanoma
NZ551355A (en) Treatment of cancer with irinotecan (CPT-11) and erlotinib
Cai et al. Catharanthine tartrate ameliorates osteoclastogenesis by destabilizing HIF-1α
IL301088A (en) Ribitol treatment
IL322689A (en) Compositions and methods of using eflornithine
IL301209A (en) Treatment methods for hidradenitis suppurativa
IL292982A (en) Methods of administering voxelotor
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
IL314334A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
IL322387A (en) Methods for reducing the risk of major adverse cardiovascular events among subjects in primary prevention
IL304911A (en) Breast cancer treatment using combination therapies including GDC-9545 and abemciclib or ribociclib